By Roger Longman
"Amazing," says Steve Projan, PhD, Wyeth 's VP and head of biological technologies. "Spectacular," adds his colleague Cavan Redmond,...
In an extraordinary series of deals, Pharma has embraced early-stage large-molecule technology, reflecting both the surging value of biologics and the severity of pipeline anemia. But many observers are skeptical the less experienced Big Pharmas can buy themselves into a brand new business with very different requirements. For start-ups, however, the news is very good--they now have two clear and viable pathways to creating shareholder value: acquisition and alliance.
By Roger Longman
"Amazing," says Steve Projan, PhD, Wyeth 's VP and head of biological technologies. "Spectacular," adds his colleague Cavan Redmond,...